Clinical efficacy of combination of oxaliplatin and vascular intervention in treatment of advanced cervical cancer and related prognostic factors

被引：2
作者：
Huang, Xinlong [1 ]
Yang, Haiyan [2 ]
Su, Zhenqing [1 ]
Wang, Junsong [1 ]
Zhang, Jianxun [1 ]
Zhang, Xinqin [2 ]
机构：
[1] First Peoples Hosp Wenling, Dept Vasc Tumor Intervent, Wenling 317500, Peoples R China
[2] First Peoples Hosp Wenling, Dept Gynecol, Wenling 317500, Peoples R China
来源：
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH | 2022年 / 21卷 / 03期
关键词：
Oxaliplatin; Vascular intervention; Advanced cervical cancer; Prognosis; CELLS;
D O I：
10.4314/tjpr.v21i3.26
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Purpose: To investigate the therapeutic effect of combination of oxaliplatin and vascular intervention in patients with advanced cervical cancer (ACC), and its influence on the prognosis of patients. Methods: One hundred ACC patients were selected and equally assigned to control (oxaliplatin) and combination or study (oxaliplatin plus vascular intervention) groups. The patients in control group received oxaliplatin, while those in study group were treated with oxaliplatin combined with vascular intervention. Clinical efficacy, levels of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor-2 (VEGFR-2), fibroblast growth factor-2 (FGF-2), BFGF and platelet-derived growth factor (PDGF) before and after therapy, and survival rate at 3, 6, 12 and 18 months after therapy were determined compared between the two groups. The prognostic factors were analyzed with logistic factor analysis. Results: The clinical efficacy and survival rate at 3, 6, 12 and 18 months after therapy in the combination group were higher when compared with those of the control group (p < 0.05). After therapy, the levels of VEGF, VEGFR-2, FGF-2, BFGF and PDGF were lower in the combination group than in control group. Age, short-term efficacy and basic diseases were identified as the influencing factors for the prognosis of patients with advanced cervical cancer (p < 0.05). Conclusion: The combination of oxaliplatin and vascular intervention significantly improved clinical treatment efficacy and survival rate in ACC patients. Age, short-term efficacy and basic diseases affected the prognosis of patients.
引用
收藏
页码：643 / 648
页数：6
相关论文
共 50 条
[31]   First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors [J].
Vivaldi, Caterina ;
Caparello, Chiara ;
Musettini, Gianna ;
Pasquini, Giulia ;
Catanese, Silvia ;
Fornaro, Lorenzo ;
Lencioni, Monica ;
Falcone, Alfredo ;
Vasile, Enrico .
INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (04) :938-945
[32]   Efficacy of apatinib as third-line treatment of advanced colorectal cancer and prognostic analysis [J].
Wang, Juchao ;
Sun, Qiang ;
Zhao, Jian ;
Li, Zengming ;
Kou, Dan ;
Qu, Dongxiang .
JOURNAL OF BUON, 2021, 26 (01) :93-100
[33]   Observation of efficacy and prognosis of chemoradiotherapy with apatinib in combination with oxaliplatin+5-fluorouracil plus leucovorin in the gastric cancer in advanced stage [J].
Zhang, R. ;
Cao, S. ;
Yu, X. ;
Zhang, D. ;
Cui, S. ;
Liu, C. ;
Cheng, X. ;
Wang, J. .
INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2021, 19 (04) :907-912
[34]   Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer [J].
Chang, Myung Hee ;
Kim, Kyoung Ha ;
Jun, Hyun Jung ;
Kim, Hyo Song ;
Yi, Seong Yoon ;
Uhm, Ji Eun ;
Park, Min Jae ;
Lim, Do Hyoung ;
Ji, Sang Hoon ;
Hwang, In Gyu ;
Lee, Jeeyun ;
Park, Yeon Hee ;
Ahn, Jin Seok ;
Ahn, Myung-ju ;
Park, Keunchil .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) :917-924
[35]   Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen) [J].
Oukkal, M. ;
Djilat, K. ;
Hadjam, R. M. ;
Mahgoun, M. T. ;
Bentabak, K. ;
Graba, A. ;
Smail, N. ;
Kaci, N. Ait ;
Ahmed, R. Baba ;
Bouzid, K. .
BULLETIN DU CANCER, 2010, 97 (04) :469-474
[36]   Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer [J].
Myung Hee Chang ;
Kyoung Ha Kim ;
Hyun Jung Jun ;
Hyo Song Kim ;
Seong Yoon Yi ;
Ji Eun Uhm ;
Min Jae Park ;
Do Hyoung Lim ;
Sang Hoon Ji ;
In Gyu Hwang ;
Jeeyun Lee ;
Yeon Hee Park ;
Jin Seok Ahn ;
Myung-ju Ahn ;
Keunchil Park .
Cancer Chemotherapy and Pharmacology, 2009, 64 :917-924
[37]   Clinical Aspects and Prognostic Factors for Survival in Patients with Recurrent Cervical Cancer after Radical Hysterectomy [J].
Hanprasertpong, Jitti ;
Jiamset, Ingporn ;
Geater, Alan ;
Rattanaburi, Athithan ;
Thannil, Sarayut .
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) :704-711
[38]   Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy [J].
Polee, MB ;
Hop, WCJ ;
Kok, TC ;
Eskens, FALM ;
van der Burg, MEL ;
Splinter, TAW ;
Siersema, PD ;
Tillanus, HW ;
Stoter, G ;
van der Gaast, A .
BRITISH JOURNAL OF CANCER, 2003, 89 (11) :2045-2050
[39]   Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy [J].
M B Polee ;
W C J Hop ;
T C Kok ;
F A L M Eskens ;
M E L van der Burg ;
T A W Splinter ;
P D Siersema ;
H W Tilanus ;
G Stoter ;
A van der Gaast .
British Journal of Cancer, 2003, 89 :2045-2050
[40]   Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence [J].
Jackson, Matthew W. ;
Rusthoven, Chad G. ;
Fisher, Christine M. ;
Schefter, Tracey E. .
ONCOTARGETS AND THERAPY, 2014, 7 :751-759
12345